CliffBio
small molecule

ZIDOVUDINE

ZIDOVUDINE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameZIDOVUDINE
Active ingredientZIDOVUDINE
Strength300MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2010
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ZIDOVUDINE patent cliff — loss of exclusivity — | CliffBio